Sleep

Latest News


Prior to the launch of solriamfetol (Sunosi) for narcolepsy and obstructive sleep apnea, the Drug Enforcement Administration designated it as a Schedule IV drug, indicating that it has a low potential for abuse and a low risk of dependence. Around the same time, results from the phase 3 TONES 3 study were published, showing the drug’s efficacy in increasing wakefulness and reducing sleepiness.

David Kingdon, MD, professor of mental health care delivery, University of Southampton, outlined some future avenues for research on the use of cognitive behavioral therapy (CBT) in psychosis, including the benefits of “worry periods” and studies on sleep.

What we’re reading, November 7, 2016: caretaker fraud within Medicaid’s Personal Care Services program left patients neglected and abused; a proposal to increase shift limits for first-year residents from 16 to 28 hours draws both support and criticism; CDC has identified 13 locally-acquired cases of antibiotic-resistant Candida auris in the US.